281209-13-0 Usage
Uses
Used in Pharmaceutical Industry:
2,6,7-Trichloro-3-(trifluoromethyl)quinoxaline is used as a building block in the synthesis of pharmaceutical compounds for its potential to contribute to the development of new drugs. Its unique structure may offer novel properties that can be harnessed in medicinal chemistry.
Used in Agricultural Industry:
In the agricultural sector, 2,6,7-Trichloro-3-(trifluoromethyl)quinoxaline is similarly used as a building block in the synthesis of agrochemicals, potentially leading to the creation of new pesticides or other compounds that can enhance crop protection and yield.
Used in Organic Synthesis:
2,6,7-Trichloro-3-(trifluoromethyl)quinoxaline is used as a key intermediate in organic synthesis for the preparation of a variety of organic compounds, leveraging its reactive sites for further chemical modifications to achieve desired molecular structures with specific properties.
Check Digit Verification of cas no
The CAS Registry Mumber 281209-13-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,8,1,2,0 and 9 respectively; the second part has 2 digits, 1 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 281209-13:
(8*2)+(7*8)+(6*1)+(5*2)+(4*0)+(3*9)+(2*1)+(1*3)=120
120 % 10 = 0
So 281209-13-0 is a valid CAS Registry Number.
InChI:InChI=1/C9H2Cl3F3N2/c10-3-1-5-6(2-4(3)11)17-8(12)7(16-5)9(13,14)15/h1-2H
281209-13-0Relevant articles and documents
Small molecule ago-allosteric modulators of the human glucagon-like peptide-1 (hGLP-1) receptor
Teng, Min,Johnson, Michael D.,Thomas, Christine,Kiel, Dan,Lakis, James N.,Kercher, Tim,Aytes, Shelley,Kostrowicki, Jarek,Bhumralkar, Dilip,Truesdale, Larry,May, John,Sidelman, Ulla,Kodra, Janos T.,Jorgensen, Anker Steen,Olesen, Preben Houlberg,de Jong, Johannes Cornelis,Madsen, Peter,Behrens, Carsten,Pettersson, Ingrid,Knudsen, Lotte Bjerre,Holst, Jens J.,Lau, Jesper
, p. 5472 - 5478 (2008/09/18)
Following our previous publication describing the biological profiles, we herein describe the structure-activity relationships of a core set of quinoxalines as the hGLP-1 receptor agonists. The most potent and efficacious compounds are 6,7-dichloroquinoxalines bearing an alkyl sulfonyl group at the C-2 position and a secondary alkyl amino group at the C-3 position. These findings serve as a valuable starting point for the discovery of more drug-like small molecule agonists for the hGLP-1 receptor.
NON-PEPTIDE GLP-1 AGONISTS
-
Page/Page column 56, (2010/02/13)
Novel non-peptide GLP-1 agonists, pharmaceutical compositions comprising them, use of the non-peptide GLP-1 agonists for the preparation of pharmaceutical compositions and methods for the treatment and/or prevention of disorders and diseases wherein an ac